- Research article
- Open Access
Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy
© The Author(s). 2016
- Received: 17 August 2015
- Accepted: 18 July 2016
- Published: 22 August 2016
Duchenne muscular dystrophy (DMD) causes progressive muscle degeneration, cardiomyopathy and respiratory failure in approximately 1/5,000 boys. Golden Retriever muscular dystrophy (GRMD) resembles DMD both clinically and pathologically. Like DMD, GRMD exhibits remarkable phenotypic variation among affected dogs, suggesting the influence of modifiers. Understanding the role(s) of genetic modifiers of GRMD may identify genes and pathways that also modify phenotypes in DMD and reveal novel therapies. Therefore, our objective in this study was to identify genetic modifiers that affect discrete GRMD phenotypes.
We performed a linear mixed-model (LMM) analysis using 16 variably-affected dogs from our GRMD colony (8 dystrophic, 8 non-dystrophic). All of these dogs were either full or half-siblings, and phenotyped for 19 objective, quantitative biomarkers at ages 6 and 12 months. Each biomarker was individually assessed. Gene expression profiles of 59 possible candidate genes were generated for two muscle types: the cranial tibialis and medial head of the gastrocnemius. SNPs significantly associated with GRMD biomarkers were identified on multiple chromosomes (including the X chromosome). Gene expression levels for candidate genes located near these SNPs correlated with biomarker values, suggesting possible roles as GRMD modifiers.
The results of this study enhance our understanding of GRMD pathology and represent a first step toward the characterization of GRMD modifiers that may be relevant to DMD pathology. Such modifiers are likely to be useful for DMD treatment development based on their relationships to GRMD phenotypes.
- Muscular dystrophy
- Duchenne muscular dystrophy
- Golden retriever muscular dystrophy
- Linear mixed-model analysis
- Gene expression
Duchenne muscular dystrophy (DMD) is an X-linked disease that causes progressive muscle degeneration in approximately 1 out of 5,000 boys . Skeletal and cardiac muscle can both be affected, and, while the disease is lethal, clinical presentations of DMD vary from patient to patient (e.g. age at diagnosis, age at loss of ambulation, body mass index, and lifespan [2, 3]). DMD patients are often wheelchair-bound by age 13  and typically succumb to cardiomyopathy and/or respiratory complications before age 30. The primary molecular cause of DMD is the absence of functional dystrophin, a protein required for proper muscle function. Mutations in the dystrophin gene, DMD , have been catalogued extensively in humans (e.g. [2, 6–8]) and it is apparent that the level of functional dystrophin is a key factor in determining the severity of disease. In-frame mutations resulting in truncated protein products cause the less-severe Becker muscular dystrophy, while mutations disrupting the reading frame cause the more-severe DMD . However, this “reading-frame rule” does not always apply: cases have been documented of children without any detectable dystrophin production who display phenotypes so mild that clinical diagnosis is ambiguous [10, 11].
Canine models for human diseases offer perspectives not provided by smaller animal models. Dogs are more physically comparable in size to humans than are mice; canine orthologs are available for approximately 92 % of human genes . The breeding structure used to propagate many dog breeds supports breed-specific stretches of genetic homogeneity, making the task of identifying contributing genes more facile in dogs as causal alleles segregate on a relatively homogeneous background. Colonies of dogs have been invaluable for understanding human conditions and developing treatments (for example, Alport syndrome ; vaccine response ); careful record-keeping and cooperation by dog owners, veterinarians and researchers can also benefit disease research .
Dog models for DMD have phenotypes that are very similar to the human condition, making them powerful for developing and testing new treatments. Preclinical studies from dogs can predict the potential success of a treatment in humans, as dog models of DMD are genetically and phenotypically comparable to the human disease  and, compared to mice, dogs are similar to humans in body and organ size and immune response . Golden retriever muscular dystrophy (GRMD) is the most extensively studied of the canine models of dystrophin-deficient muscular dystrophy. GRMD is remarkably similar to DMD both clinically and pathologically [18, 19]. Like DMD, dogs with GRMD are afflicted with a progressive, fatal disease with limb skeletal muscle, cardiac and respiratory involvement .
While DMD can be caused by many different types of mutations in humans, GRMD is caused by a single splice-site mutation that results in a frame shift and prematurely truncated, nonfunctional protein product . GRMD carrier females can be artificially inseminated by GRMD-affected males to produce GRMD-affected females, which do not differ phenotypically from males; affected females (aside from a few rare “manifesting carriers” [22, 23]) have not been seen in humans.
As a first step toward characterizing genetic modifiers of GRMD, we performed a pilot study using linear mixed-model (LMM) analysis of 8 variably-affected dystrophic dogs and 8 non-dystrophic dogs, all either full or half-siblings, with complete data available for age-specific phenotypic measurements. We have also compared our LMM findings with a cohort of unrelated dogs to evaluate the GRMD population relative to a broader population. GRMD disease grows progressively worse with age and marked variation in disease severity is observed between different muscles [20, 24], which suggests that genetic modifiers of GRMD disease act differentially between muscles. We have therefore included two different age groups and two muscle types (the cranial tibialis – a flexor, and the medial head of the gastrocnemius – an extensor) in our analysis to evaluate how gene expression changes with each variable. These dogs were extensively phenotyped using biomarkers that correlate with disease severity on multiple levels (for example, force generated by different muscle groups).
These LMM analyses provide a foundation for future research, including fine-mapping of phenotype-associated modifier loci, targeted sequencing, and proteomics.
All GRMD dogs used in this study were from the colony at the University of North Carolina at Chapel Hill, now located at Texas A&M University. The dogs were maintained and treated according to the standards of the National Research Council Guide for the Care and Use of Laboratory Animals. Blood creatine kinase levels taken shortly after birth were used to diagnose neonates with GRMD , along with PCR as previously described . The colony is primarily maintained by mating hemizygous GRMD males to carrier females to produce approximately equal numbers of affected males and females.
Sixteen dogs were selected for this study based on the availability of phenotypic data. This cohort included 8 GRMD-affected and 8 unaffected dogs from two age groups: ~6 months (n = 9) and ~12 months (n = 7) of age. The 6-month-old group contained 4 normal (all male) and 5 affected (1 female and 4 males); the 12-month-old group contained 4 normal (all male) and 3 affected (2 females and 1 male). These 16 dogs represented 5 litters; 13 of the dogs were half-sibs and the remaining 3 were cousins to the other dogs. Three of the 5 litters included both normal and affected dogs.
Genotype data was also obtained for 19 unrelated and unaffected golden retrievers for which muscle tissue samples were not available.
Samples of muscle tissue were collected from the medial head of the gastrocnemius and cranial tibialis at necropsy, flash-frozen in liquid nitrogen, and subsequently stored at −80 °C.
The phenotypes/biomarkers evaluated in this study were developed for use in preclinical trials in GRMD dogs, and are objective and quantitative. Detailed descriptions of each biomarker and the method(s) of measurement have been published previously [20, 24, 26–32] and include: body-mass-corrected tibiotarsal joint (TTJ) tetanic flexion and extension force (Newtons/kg; ), tibiotarsal joint angle (degrees; ), eccentric contraction decrement (ECD) at 10 and 30 stimulations (percent; [29, 30]), maximum hip flexion angle (degrees; ), pelvic angle (degrees; ), body-mass-corrected cranial sartorius circumference (mm/kg; ), quadriceps femoris weight (g) and quadriceps femoris weight corrected for body weight (g/kg) , body weight (in kg) measurements taken at 1 month, 6 months, and 12 months of age , and ratios of body weight to birth weight for each time point (percent) .
The biomarkers used for this study provide objective indices of disease severity. Because pathologic data were collected at necropsy, we were able to assess terminal muscle weights to gain further insight on the degree of atrophy or hypertrophy. As an example, absolute and body-mass-corrected weight of the quadriceps femoris, the principal muscle involved in stifle (knee) extension was assessed. Other biomarkers assessed functional parameters relevant to specific muscles used for validation of candidate genes. Most notably, the cranial tibialis and gastrocnemius are the principal muscles contributing to TTJ tetanic flexion and extension, respectively. Tibiotarsal joint, maximum hip flexion, and pelvic joint angle measurements provided objective insight on the severity of debilitating contractures and postural instability in GRMD and served as surrogates for overall muscle imbalance and weakness that ultimately cause loss of ambulation in severely affected dogs .
DNA samples from the 16 GRMD affected and control dogs, along with the 7 parental samples, were genotyped on the Illumina CanineHD BeadChip (Illumina Inc, San Diego, CA) and scored at GeneSeek (Lincoln, NE). Furthermore, DNAs from 19 golden retrievers, unrelated to the colony as well as to one another, were genotyped on the same array to increase confidence in our results and to evaluate the GRMD population relative to a broader population, as described below.
Linear mixed-model (LMM) analyses were performed using three different methods to reduce the number of false associations identified, and to overcome biases inherent to each methodology. Data from all dogs were assessed by all three algorithms, which perform linear mixed models based on clustering to account for both population substructure and relatedness via a kinship matrix estimated from identical by descent distances.
Associations between SNPs and biomarkers were initially identified using the whole genome association analysis program plink . Each biomarker was assessed separately as its own endophenotype. SNPs were filtered and pruned to reduce spurious associations. Inclusion thresholds were 10 % maximum per-SNP missing, 5 % maximum per-dog missing, and 10 % minimum minor allele frequency (MAF). After applying these filters, 125,665 SNPs remained for analysis on all 16 dogs. Population stratification was estimated for each endophenotype using the genomic control λ value calculated by plink; a λ value of 1 indicates no stratification, meaning association results are not likely to be influenced by population structure . For plink results, adjustment for multiple testing was done by using Bonferroni procedure with p-value cutoff of 3.98 × 10−7 (=0.05/125665) to give p genome-wide < 0.05.) We subsequently performed association studies using Genome-wide efficient mixed-model association (GEMMA)  and SNP and Variation Suite (SVS) (version 8.1.1) software to confirm the robustness of associations, similar to strategies used in previous studies [39–41]. The linear mixed-model analysis GEMMA allowed us to eliminate false associations due to breeding structure. We performed three association tests: the Wald test, likelihood ratio test, and score test, as described in the GEMMA manual . We furthermore used the Efficient Mixed-Model Association (EMMA) approach in SVS with the EMMAX (EMMA eXpedited) technique for normalizing the kinship matrix [43, 44]. Results were further analyzed using R software  to develop manhattan plots to visualize associations. Because the GRMD population used in this study consists of related individuals, we used multidimensional scaling (MDS) via plink to identify sample clustering and population stratification with and without the unrelated population of 19 golden retrievers.
The causal mutation responsible for GRMD has been previously identified in the DMD gene  (located on the canine X chromosome, positioned between bases 26290903–28444623; canine genome assembly version 3.1, Sept. 2011). Association with SNPs residing near or within the DMD, using case–control analyses, confirmed the causal relationship between GRMD and the DMD gene.
SNP effect prediction
All SNPs found to be statistically-significant via LMM analysis were evaluated to determine possible effects of SNPs on genes, transcripts, and protein sequences using Ensembl’s Variant Effect Predictor .
Haplotyping and linkage disequilibrium
Since contributing loci are likely to be co-inherited with significantly-associated SNPs, we developed haplotypes using plink software  for those chromosomes containing significantly associated SNPs. Blocks of linkage disequilibrium (LD) were then visualized with Haploview .
Candidate modifier gene identification
Chromosomes and regions of LD found to harbor SNPs statistically associated with one or more biomarkers were manually examined to identify candidate genes. We used the BioMart tool from the Ensembl genome browser to extract information about positions and functions of genes within regions of interest in the canine genome, together with information about human orthologs, where available. At the same time, we searched the NCBI database for gene information, including associated phenotypes. Both databases provided information about gene ontologies and interactions, providing additional evidence to support possible roles for candidate genes modifying GRMD phenotypes. Relevant publications, listed in the Bibliography section of the gene reference pages on NCBI, and Gene References into Function (GeneRIFs) were also used to identify potential candidate genes. Genes were selected for qPCR analysis if their known or predicted function(s) were consistent with the pathogenesis of muscular dystrophy (such as roles in skeletal muscle or cardiac function), or if they interacted with other gene(s) or pathway(s) relevant to the GRMD phenotypes being studied.
Total RNA was extracted from necropsy samples from the cranial tibialis and medial head of the gastrocnemius muscles archived at −80 °C for each of the 16 dogs using TriPure Isolation Reagent (Roche; Indianapolis, IN) as per manufacturer’s instructions. RNA was precipitated using isopropanol and 75 % EtOH, and dissolved in ultra-pure water. To minimize DNA contamination, samples were DNase-treated using the DNA-Free DNase Treatment and Removal kit (Ambion). The RNA concentrations in the individual samples were measured using a Nanodrop 2000 spectrophotometer and assessed for quality on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). The RIN values ranged from 7.5 – 8.2, with the exception of one sample which had a RIN value of 6.7. The Standards read 9.
Quantitative PCR (qPCR)
Total RNA was directly reverse transcribed to cDNA using SuperScript II (Invitrogen). Briefly, samples of skeletal muscle DNase-treated RNA (100 ng) were reverse transcribed with oligo-dT and random primers and Superscript II (Invitrogen, Carlsbad, CA). The reverse transcription reactions consisted of 100 ng of DNase-treated RNA in a 50 μl reaction, ultra pure water, oligo dT (2.5 μl of 500 ng/μl) and random hexamer (0.48 μl of 1 mM stock) heated to 65 °C for 5 min and cooled to room temperature. Next, Superscript II (2 μl), 5X 1st Strand buffer (10 μl), 0.1 M DTT (5 μl), 10 mM dNTPs (2.5 μl) and an RNase block Ambion’s Superasin (1 μl) were added to the mix. All were heated to 37 °C for one hour followed by reverse transcription inactivation at 90 °C for 5 min.
TaqMan® Gene Expression assays (Life Technologies, Grand Island, NY; [48, 49]) were used to measure expression levels for 51 genes identified within candidate gene regions. qPCR using TaqMan assays was performed using MicroAmp Fast Optical 96 well plates (Applied Biosystems). The qPCR reactions for each TaqMan assay consisted of 10 μl TaqMan Gene Expression Master Mix, 1 μl TaqMan assay, 8.5 μl PCR grade water, and 0.5 μl of each reverse transcription reaction (cDNA) for a total of 20 μl per well. TaqMan assays were not available for an additional 8 genes; for these, we used SYBR Green technology to determine expression levels. Primers for genes assessed via SYBR Green were designed from two neighboring exons flanking one intron (when possible), or from a single exon, using Primer3 software (http://biotools.umassmed.edu/bioapps/primer3_www.cgi; ). Each 20 μl reaction contained 10 μl Power SYBR Green PCR Master Mix (Applied Biosystems), 2 μl each forward and reverse primers (3 μM each), 5.5 μl ultra-pure water, and 0.5 μl (1 ng) cDNA for a total of 20 μl per well. All qPCR reactions were performed in duplicate using the 7900HT Fast qPCR System (Applied Biosystems); primer and assay information is listed in Additional file 1: Table S1. The cycling parameters on the 7900HT machine were 50 °C for 2 min, 95 °C for 10 min, and cycling 40 repeats of 95 °C for 15 s and 60 °C for 1 min. The parameters were the same for the Sybr assays with a dissociation curve added to validate primers.
No single housekeeping gene could be identified as having steady expression levels across both muscle types and age groups interrogated; therefore we used the geometric mean strategy for data normalization, in which the normalization factor is calculated using multiple genes, as described . Differential gene expression was statistically evaluated via unpaired t-test using GraphPad QuickCalcs Web site: http://graphpad.com/quickcalcs/ttest1.cfm (accessed July 2014 ). Expression levels were considered significant at p < 0.05.
Linear regression correlating gene expression with clinical phenotype measurements
Simple linear regression analyses between specific GRMD quantitative phenotypes and expression values obtained for each GRMD-affected dog were performed for each of the 39 potential candidate genes identified by the LMM analyses. All phenotype-transcript regression pairs with a correlation coefficient (R 2) value of ≥0.8 were considered significant.
Genomic control factors
Case/control association using plink confirmed the causal mutation on Canis familiaris chromosome X CFAX, with a genomic inflation factor λ = 1.
Genomic inflation factors calculated for GRMD biomarkers. The biomarkers that are the most robust against stratification are shaded
TTJ Tetanic flexion (N/kg)
TTJ Tetanic extension (N/kg)
Percent eccentric contraction decrement (at 10 stimulations)
Percent eccentric contraction decrement (at 30 stimulations)
Maximum hip flexion angle
Cranial sartorius circumference (mm/kg)
Quadriceps femoris weight (g)
Quadriceps femoris weight (g/kg body weight)
Body weight at birth (kg)
Body weight at age 1 month (kg)
Percent body weight gain: birth-1 month
Body weight at age 6 months (kg)
Percent body weight gain: birth-6 months
Body weight (kg) at age 12 months
Percent body weight gain: birth-12 months
Nine SNPs were most strongly associated with GRMD biomarkers following Bonferroni correction. The first column lists canine chromosome number and second column lists base-pair location of the SNP (based on CanFam3.1). The third column gives the SNP identifier
SNPs from the associated regions on CFA7, 9, 23, and X were evaluated for potential consequences using the Ensembl Variant Effect Predictor tool . No SNPs were found to affect amino acid sequences, or alter codons. Furthermore, no co-located variations were found. The Variant Effect Predictor output is provided in Additional file 3: Table S3.
Candidate gene identification
Regions of CFA 7, 9, 23, and X share synteny with regions of the human genome which harbor loci encoding proteins with functions relevant to DMD/GRMD.
SNPs were identified in a ~19 Mb region of CFA7, which shares homology with HSA18. In both species, this region comprises a number of genes encoding proteins involved in muscle and/or cardiovascular function. For example, several of these proteins are associated with dystrophin/muscle (dystrobrevin alpha - DTNA; laminins alpha and gamma - LAMA1 and LAMC1; lamin a – LMNA; and myomesin 1 – MYOM1). Others are associated with cardiomyopathy, such as that observed in DMD and GRMD (desmocollin 2 – DSC2; desmoglein 2 – DSG2). We therefore investigated 11 candidate genes in this section of the dog genome.
A 2 Mb region on CFA9 was associated with TTJ tetanic flexion measurements. This section of CFA9 is homologous to segments of HSA15 and HSA9. Unlike CFA7, this region is not home to many genes with obvious potential roles in GRMD. We investigated one gene, RAPGEF1, located on CFA9, which we identified as the most likely to play a role in GRMD of the few genes in this region.
The significant SNP associations found on CFA23 spotlighted two regions: a ~3 Mb region associated with ECD at 30 stimulations, and a single SNP near the 12.8 Mb position of the chromosome, associated with percent body weight gain from birth to one month of age. Much of CFA23 shares homology with HSA3; we evaluated 3 candidate genes from this chromosome for expression differences in our GRMD cohort.
We measured transcripts for three different sections of DMD, and for additional loci on CFAX based on the locations of associated SNPs. In total, we evaluated expression levels for 7 loci on CFAX.
Genes outside of the regions of initial interest were also considered for validation because of their biological relevance.
CFA18, homologous to HSA11, was not quite as strongly correlated with GRMD biomarkers – in fact, the 2 SNPs on CFA18 identified in this study were found to be only nearly significant (FDR p-value = 0.06) and were associated with percent body weight gain from birth to one month of age. However, the chromosome contains several genes encoding proteins with functions pertaining to skeletal muscle phenotypes or neuromuscular junction development; therefore, we investigated the expression levels of 16 genes from CFA18.
We investigated the transcript levels of 20 more genes from chromosomes that were not found to harbor significantly-associated SNPs. Several of these genes were evaluated as potential “housekeeping” genes for normalization (including ACTB, GUSB, PPIA, and PSMD2), and most were not found to be suitable for this role because they showed variable expression levels across dogs. However, we chose to continue to investigate some of these genes as potential candidate modifiers based on their functions in related conditions (for example, GUSB; see below). Others of this group of genes encode proteins that have been suggested as modifiers in DMD or mdx, and/or are involved in muscle regeneration and degeneration, or were strongly associated in follow-up LMM analyses by GEMMA or SVS (e.g., telomerase reverse transcriptase, TERT).
In total, we investigated 58 transcripts for differential expression in GRMD and normal dogs. Gene names, genomic positions and qPCR primer information for these transcripts are listed in Additional file 1: Table S1.
Correlations between gene expression levels and phenotypic measurements
We used qPCR to measure the expression of candidate “modifier genes” in the cranial tibialis and medial head of the gastrocnemius muscles of the same dogs used for the mixed-model study. Relative expression data were calculated using the ΔΔCt method of Livak and Schmittgen , and normalized to the geomean. Of the original set of 58 genes, 12 were dropped from further analysis due to inconsistent measurements across replicates. In total, we measured the expression levels of 46 gene transcripts.
Linear regression correlating gene expression with clinical phenotype measurements
What is most interesting about the correlations found via linear regression is the specificity of muscle type observed in these relationships: correlations found between transcript levels in the medial head of the gastrocnemius vs those seen in the cranial tibialis. These results reflect the differences in muscle injury in GRMD, further suggesting that future treatment regimens could be tailored to muscle type for maximum effectiveness. Here, all correlations described involve 6-month-old dystrophic dogs (n = 5). There were only 3 dystrophic 12-month-old dogs, making linear regression analysis less powerful for this age group; therefore we do not discuss here the analysis for this cohort.
In the cranial tibialis muscle, transcripts from the DMD2 primer set, located near exons 7–8 of the DMD gene, were decreased with greater tetanic flexion values. It is unclear whether any of this transcript was translated into a protein; the transcript was likely subject to nonsense-mediated decay and therefore it is difficult to make a true connection between this biomarker and DMD2 levels. We found that decreasing levels of desmoglein 2 (DSG2) transcript within the cranial tibialis muscle were correlated with increasing measurement values for tetanic flexion. DSG2 encodes a calcium-binding transmembrane glycoprotein which has been implicated in right ventricular cardiomyopathy . While cardiomyopathy is indeed a part of GRMD disease, here we observed transcriptional activity within skeletal muscle. Next, laminin, alpha 1 (LAMA1) transcript levels decreased in the cranial tibialis in tandem with increasing quadriceps femoris weight (when corrected for body weight) at age 6 months. LAMA1 encodes the laminin a1 chain of the laminin-111 heterotrimer, a protein previously investigated for therapeutic potential in mdx mice . Additionally, low density lipoprotein receptor-related protein 4 (LRP4) is involved with the maintenance of neuromuscular synapse formation and neuromuscular junction . We associated higher levels of LRP4 transcript in the cranial tibialis with larger tetanic extension measurements. Finally, transcript levels of a gene called peptidase domain containing associated with muscle regeneration 1 (PAMR1) in the cranial tibialis associated linearly with eccentric contraction decrement at 10 stimulations as well as quadriceps femoris weight when corrected for body weight. In both instances, increases in the amount of PAMR1 transcript were correlated with increases in measurement values of these biomarkers. Overall, the cranial tibialis muscle showed the most linearity between transcript levels of candidate modifier genes and biomarker measurement values.
The medial head of the gastrocnemius muscle is affected differently than the cranial tibialis. Not surprisingly, transcript levels of different candidate genes were associated with GRMD biomarkers. In another example of linear correlation, beta glucuronidase (GUSB) expression levels in the medial head of the gastrocnemius of 6-month-old GRMD dogs decreased with increased tetanic extension measurements (R 2 = 0.81), which also suggest a relationship between transcript levels of these genes and GRMD phenotype. Also in the medial head of the gastrocnemius of 6-month-old GRMD dogs, transcript levels of laminin, beta 1 (LAMB1) correlated nearly perfectly with measurements of quadriceps femoris weight (R 2 = 0.83 for muscle weights themselves, and R 2 = 0.98 when overall body weight was also taken into consideration). In other words, increased weight of the quadriceps femoris was associated with decreased levels of LAMB1. Furthermore, LAMB1 expression correlated well with eccentric contraction decrement measurements after 10 stimulations. LAMB1 is one of several extracellular matrix glycoproteins and has been previously associated with muscular dystrophies – particularly limb-girdle muscular dystrophy, where LAMB1 levels have been observed to be decreased .
Comparisons of expression at different ages
In the cranial tibilalis of 6-month-old dogs, expression was significantly different between GRMD and normal dogs for 11 genes; for 12-month-old dogs, a significant difference was seen for 12 genes (including 6 of the same genes that were differentially expressed at age 6 months). In the medial head of the gastrocnemius, we found 4 genes to have significantly different expression levels between GRMD and normal dogs at age 6 months. 3 of these remained significant in comparisons at 12 months of age, along with 5 additional genes.
Comparisons of expression in different muscles and at different ages
While the cranial tibialis and medial head of the gastrocnemius are both located in the distal pelvic limb, their functions differ. The cranial tibialis is a flexor of the tibiotarsal joint, while the medial head of the gastrocnemius is an extensor. Natural history functional data indicate that TTJ flexors are affected relatively early in the disease course and recover to some extent . On the other hand, TTJ extensors are affected later in the disease course. Similarly, the medial head of the gastrocnemius undergoes considerably greater atrophy than the cranial tibialis .
The two muscles we evaluated have different (often opposite) functions in GRMD clinical signs, and expression level comparisons between affected and unaffected dogs were found to be significant in both muscles for only the DMD gene, as expected. DMD2 was significant in both age groups in the cranial tibialis and at 6 months in the medial head of the gastrocnemius, while differential expression of DMD3 was significant at both ages in the cranial tibialis.
Overall, more genes were differentially-expressed in the cranial tibialis than the gastrocnemius. This could be due to the fact that the cranial tibialis is affected earlier in the course of GRMD disease. Some of these differentially-expressed genes had statistically-significant expression differences specifically in one muscle but not the other, an observation which could have implications for the different ways these muscles function in GRMD. Beta glucuronidase (GUSB) was originally selected as a possible housekeeping gene for normalization, but surprisingly we found the expression of GUSB to vary substantially. We observed that GUSB expression levels were increased in the cranial tibialis in GRMD relative to normal dogs at both ages, while levels in the gastrocnemius were fairly equal. Likewise, laminin gamma 1 (LAMC1), peptidase domain containing associated with muscle regeneration 1 (PAMR1) and peptidylprolyl isomerase A (PPIA) expression differences were significant only in the cranial tibialis. However, these differences were significant in both 6- and 12-month-old age groups.
Similarly, 3 genes showed significant differential expression only in the medial head of the gastrocnemius. These included lipase, member H (LIPH), phosphodiesterase 8B (PDE8B) and slit guidance ligand 2 (SLIT2). Each of these genes was found to have significant differences in expression level between dystrophic and non-dystrophic dogs at both ages.
We observed age-specific differential expression for FXR1 (fragile X mental retardation, autosomal homolog 1) and thrombospondin 4 (THBS4). Both of these genes showed the greatest differences in expression level at 12 months of age. This could reflect the increased severity of GRMD disease at 12 months compared to 6 months of age, or it could highlight a specific phase of development during which these genes are most active. The protein encoded by FXR1 plays a role in myogenesis , while THBS4 is involved in nervous system development.
Transcription of the DMD gene
We found measurable transcript levels of the DMD gene in the 8 dystrophic GRMD dogs. These levels varied based on the locations of the primers within DMD, and muscle type. Paradoxically, in both the cranial tibialis and gastrocnemius, transcript levels were higher in GRMD versus non-dystrophic dogs for all three sections of the DMD gene. However, in both muscle types, transcript levels were not the same for all three segments of DMD.
Statistically-significant up-regulation of DMD transcripts was found in the cranial tibialis at age 6 months in dystrophic versus non-dystrophic dogs. By age 12 months, however, only transcripts representing some of the 5’ part of the gene (known here as DMD2, with primers designed across exons 7–8) were found to be significantly increased, both for the cranial tibialis and the medial head of the gastrocnemius. While it is not surprising to find evidence of transcription upstream of the causal GRMD mutation, the findings for primers DMD1 and DMD3 were unexpected. These assays represent sections of the DMD gene that are farther downstream (exons 46–47 and 69–70, respectively), yet measurable transcription was observed in the cranial tibialis of 6-month-old dogs. Moreover, these transcripts were significantly up-regulated in GRMD dogs when compared with non-dystrophic dogs.
DMD transcripts have been previously identified in the cranial sartorius and vastus lateralis muscles of dystrophic dogs  as well as in dystrophic mice ; however, these transcripts were more often found to be from the 5’ end of the gene sequence than the 3’end. This imbalance was postulated to explain the observed transcription of DMD in these studies, an explanation that may apply to some of our own findings from the cranial tibialis. These and other studies also suggest that these rogue DMD transcripts are likely to be subject to nonsense mediated decay and completely nonfunctional at the protein level [65–67]. However, our lab has found evidence of protein expression (M. Schneck, personal communication) which suggests that translation of these DMD transcripts takes place to some extent.
Previous studies have postulated that exon-skipping can occur in human DMD, in cases where a causal point mutation either disrupts enhancer sequences or creates suppressor sequences leading to atypical exon splicing [68, 69]. Such situations could instigate exon skipping, resulting in variable levels of dystrophin production [70–75]. Mutations within certain regions of DMD tend to be more prone to this type of phenomena, which may explain some of the phenotypic variation in DMD : alternate start codons or alternate splicing in the 5’ (proximal) end of the DMD gene can “rescue” the dystrophin transcript [4, 76–78]. This region includes intron 7, which is highly susceptible to mutation in humans [79, 80]. Importantly, this region is also homologous to that of the GRMD causal mutation . Therefore, it is possible that DMD transcription and translation in GRMD dogs can be explained by exon-skipping; we intend to investigate this theory via sequencing and additional protein studies.
The clinical variability seen in DMD suggests that disease outcome is influenced by genetic modifiers of the causal mutation in the DMD gene. Genetic modifiers that influence phenotypes can serve as additional druggable targets for treatment. In humans, the search for genetic modifiers is confounded by the large number of mutations associated with DMD and the absence of defined genetic populations. Animal models of the disease are useful for discovery of genetic modifiers because the genetic backgrounds are relatively homogeneous, particularly for the causal DMD mutation. However, the use of models that do not resemble the human disease may limit the relevancy of modifiers discovered.
The GRMD colony at Texas A&M University is fairly inbred yet sufficiently genetically diverse to study complex phenotypes such as those observed in DMD. All GRMD dogs are descended from the same founding sire and all share a common causal mutation, but variation is observable in the progression of disease and severity of the phenotype . The breeding strategy employed is such that the Texas A&M GRMD colony possesses many of the advantages of an inbred population (e.g. reduced influence of confounding factors such as environmental variation), but unlike inbred mice, GRMD dogs feature genetic diversity more similar to that found in human populations. The identification of genetic modifiers is therefore simplified by using our GRMD colony and requires a smaller sample size than would a study using humans . Understanding the role(s) of genetic modifiers of GRMD may identify genes and pathways that also modify phenotypes in DMD and reveal novel therapies.
This study represents a preliminary characterization of the GRMD model to identify potential candidate modifier genes. The extensive LD found in many dog breeds allows the efficient identification of causal genetic variants for Mendelian conditions. However, finding modifier genes for more complex phenotypes is less straightforward. Populations where heterozygosity is more prevalent than seen in typical inbred populations add to the challenge, but can provide results that are arguably more relevant to a broader population. The analyses described here are meant to serve as a pilot study for evaluating the likelihood of genetic modifiers of GRMD phenotypes. We anticipate that our findings will provide a starting point for additional studies.
In this paper we have presented evidence for genetic influences on objective phenotypic biomarkers in GRMD. Our study allowed us to compare mildly and severely affected GRMD dogs with high degrees of relatedness without confounding factors such as environmental differences. We used a sample set that included GRMD affected dogs of both genders, but as in previous studies we did not see any significant gender-specific difference in biomarker measurements. With our small cohort of dogs, we identified regions that correlated with GRMD biomarkers in some way, perhaps directly or as a part of a larger pathway. It should be noted that the applicability of the results we describe here are limited to the GRMD model, though the putative candidate genes we have identified provide support for future investigations toward the identification and characterization of modifier genes. Because of the high degree of similarity between GRMD and DMD, such searches are of utmost importance to expand and enhance the relevance and applicability of this animal model for understanding the “minor players” (called “secondary effects” versus “primary” effects of dystrophin deficiency; ) of DMD disease variation (e.g., the underlying genetic background affecting variant DMD phenotypes) and for developing novel therapeutics (e.g., trials for drugs and other experimental therapies). While the power of this particular study is limited by the small number of subjects, our results indicate that GRMD phenotypes are, indeed, susceptible to genetic background.
The fact that qPCR values for the same genes differed between muscles suggests that pathways or mechanisms vary for individual muscles. As expected, there was also differential expression with age, reflecting the stage of disease. While this is not surprising, the implications must be considered when evaluating the outcomes of clinical trials. It may be that targeted treatments will be a preferable option for some patients for whom other therapies (e.g. stem cell, gene replacement, or chemical) have failed to produce satisfactory results. In these situations, understanding the involvement of specific sets of genes on different muscles or time points could lead to treatments that, for example, improve one aspect of DMD disease without detrimentally affecting others.
For monogenic conditions such as DMD that show a spectrum of phenotypes, there is tremendous value in identifying potential modifiers. Such modifiers could influence outcomes of therapeutic trials performed using GRMD as a model for DMD. On the other hand, modifiers may also serve as targets for novel therapeutics. Detecting these genes, therefore, facilitates the role that the GRMD model plays in accelerating DMD treatment development. Characterization of genomic variation underlying GRMD phenotypic variation will present a powerful resource for understanding the molecular causes behind variable DMD phenotypes.
CFA, Canis familiaris chromosome; R2, correlation coefficient; CT, cranial tibialis; DMD, Duchenne muscular dystrophy; DMD, dystrophin gene; ECD, eccentric contraction decrement; EMMA, Efficient Mixed-Model Association; EMMA eXpedited, EMMAX; FDR, false-discovery-rate; GeneRIFs, Gene References into Function; GEMMA, Genome-wide efficient mixed-model association; GRMD, Golden Retriever muscular dystrophy; HSA, Homo sapiens chromosome; LMM, linear mixed-model; LD, linkage disequilibrium; MHG, medial head of the gastrocnemius; MAF, minor allele frequency; MDS, multidimensional scaling; quad fem wt g, quadriceps femoris weight in grams; qRT-PCR, quantitative reverse transcriptase PCR; SNP, single nucleotide polymorphism; SVS, SNP and Variation Suite; TTJ, tibiotarsal joint
The authors gratefully acknowledge Amanda Bettis and Heather Barnett for their roles in managing the GRMD colony at Texas A&M, and Janet Bogan, Dan Bogan, and Jennifer Dow for their assistance with the colony when it was located at University of North Carolina. Dr. Leif Andersson, Dr. Danika Bannasch and Dr. Loren Skow are also appreciated for their helpful comments regarding the design and analysis of this work.
NINDS grant 1U24NS059696-01A1, the Co-operative Program in Translational Research: Proposal for Establishment of the National Center for Canine Models of Duchenne Muscular Dystrophy, and a Muscular Dystrophy Association Infrastructure grant to the Translational Research Advisory Committee (J.N.K.).
Availability of data and material
The data sets supporting the results of this article are available in the Genome Zoo repository, http://dog.genomezoo.net/, and in its supporting files.
CB-L carried out the association studies, evaluated SNP effects, performed haplotyping and linear regression analyses as well as all statistics, and drafted the manuscript. CB-A performed qRT-PCR experiments. JC provided assistance with all association studies and feedback while drafting the manuscript. BWD provided unrelated golden retrievers for comparison analyses and feedback on the methods and manuscript. JNK provided GRMD colony samples and phenotype data. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Dogs received care and were assessed according to principles outlined in the National Research Council Guide for the Care and Use of Laboratory Animals. Studies were approved by the UNC-CH Institutional Animal Care and Use Committee (IACUC) through UNC IACUC 09–351, Standard Operating Procedures—Canine X-Linked Muscular Dystrophy.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mendell JR, Shilling C, Leslie ND, Flanigan KM, All-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304–13.View ArticlePubMedGoogle Scholar
- Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat. 2009;30:1657–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Magri F, Govoni A, D’Angelo MG, Del Bo R, Ghezzi S, Sandra G, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258:1610–23.View ArticlePubMedGoogle Scholar
- Malhotra SB, Hart KA, Klamut HJ, Thomas NS, Bodrug SE, Burghes AH, et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science. 1988;242:755–9.View ArticlePubMedGoogle Scholar
- Hoffman E, Brown RJ, Kunkel L. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.View ArticlePubMedGoogle Scholar
- Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34:135–44.View ArticlePubMedGoogle Scholar
- Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009;30:934–45.View ArticlePubMedGoogle Scholar
- White SJ, den Dunnen JT. Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res. 2006;115:240–6.View ArticlePubMedGoogle Scholar
- Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90–5.View ArticlePubMedGoogle Scholar
- Hattori N, Kaido M, Nishigaki T, Inui K, Fujimura H, Nishimura T, Naka T, Hazama T. Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy. Neuromuscul Disord. 1999;9:220–6.View ArticlePubMedGoogle Scholar
- Dubowitz V. Enigmatic conflict of clinical and molecular diagnosis in Duchenne/Becker muscular dystrophy. Neuromuscul Disord. 2006;16:865–6.View ArticlePubMedGoogle Scholar
- Goodstadt L, Ponting CP. Phylogenetic reconstruction of orthology, paralogy, and conserved synteny for dog and human. PLoS Comput Biol. 2006;2:e133.View ArticlePubMedPubMed CentralGoogle Scholar
- Nabity MB, Lees GE, Cianciolo R, Boggess MM, Steiner JM, Suchodolski JS. Urinary biomarkers of renal disease in dogs with X-linked hereditary nephropathy. J Vet Intern Med. 2012;26:282–93.View ArticlePubMedGoogle Scholar
- Soutter F, Kennedy LJ, Ollier WE, Solano-Gallego L, Catchpole B. Restricted dog leucocyte antigen (DLA) class II haplotypes and genotypes in Beagles. Vet J. 2015;203:345–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Davis BW, Ostrander EA. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 2014;55:59–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Duan D. Duchenne muscular dystrophy gene therapy: Lost in translation? Res Rep Biol. 2011;2011:31–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Nowend KL, Starr-Moss AN, Murphy KE. The function of dog models in developing gene therapy strategies for human health. Mamm Genome. 2011;22:476–85.View ArticlePubMedGoogle Scholar
- Kornegay JN, Tuler SM, Miller DM, Levesque DC. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve. 1988;11:1056–64.View ArticlePubMedGoogle Scholar
- Valentine BA, Cooper BJ, de Lahunta A, O’Quinn R, Blue JT. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci. 1988;88:69–81.View ArticlePubMedGoogle Scholar
- Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR, Okamura CS. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord. 2003;13:493–500.View ArticlePubMedGoogle Scholar
- Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics. 1992;13:115–21.View ArticlePubMedGoogle Scholar
- Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet. 1999;353:2116–9.View ArticlePubMedGoogle Scholar
- Moser H, Emery AE. The manifesting carrier in Duchenne muscular dystrophy. Clin Genet. 1974;5:271–84.View ArticlePubMedGoogle Scholar
- Kornegay JN, Bogan DJ, Bogan JR, Childers MK, Cundiff DD, Petroski GF, Schueler RO. Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. J Neurol Sci. 1999;166:115–21.View ArticlePubMedGoogle Scholar
- Bartlett RJ, Winand NJ, Secore SL, Singer JT, Fletcher S, Wilton S, et al. Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res. 1996;57:650–4.PubMedGoogle Scholar
- Kornegay JN, Sharp NJ, Bogan DJ, Van Camp SD, Metcalf JR, Schueler RO. Contraction tension and kinetics of the peroneus longus muscle in golden retriever muscular dystrophy. J Neurol Sci. 1994;123:100–7.View ArticlePubMedGoogle Scholar
- Kornegay JN, Sharp NJ, Schueler RO, Betts CW. Tarsal joint contracture in dogs with golden retriever muscular dystrophy. Lab Anim Sci. 1994;44:331–3.PubMedGoogle Scholar
- Jaegger G, Marcellin-Little DJ, Levine D. Reliability of goniometry in Labrador Retrievers. Am J Vet Res. 2002;63:979–86.View ArticlePubMedGoogle Scholar
- Tegeler CJ, Grange RW, Bogan DJ, Markert CD, Case D, Kornegay JN, Childers MK. Eccentric contractions induce rapid isometric torque drop in dystrophin-deficient dogs. Muscle Nerve. 2010;42:130–2.View ArticlePubMedPubMed CentralGoogle Scholar
- Childers MK, Bogan JR, Bogan DJ, Greiner H, Holder M, Grange RW, Kornegay JN. Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. Front Pharmacol. 2011;2:89.PubMedGoogle Scholar
- Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Grange RW. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. Methods Mol Biol. 2011;709:105–23.View ArticlePubMedGoogle Scholar
- Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome. 2012;23:85–108.View ArticlePubMedPubMed CentralGoogle Scholar
- Kornegay J, Childers M, Bogan D, Bogan J, Nghiem P, Wang J, et al. The Paradox of Muscle Hypertrophy in Muscular Dystrophy. In: Recent Advancements in Neuromuscular Medicine Edited by Carter G, vol. 23. Phys Med Rehabil Clin N Am. 2012;23:149.View ArticlePubMedGoogle Scholar
- Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1982.Google Scholar
- Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979;7:1513–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu C, DeWan A, Hoh J, Wang Z. A comparison of association methods correcting for population stratification in case–control studies. Ann Hum Genet. 2011;75:418–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nat Genet. 2012;44:821–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. Nat Rev Genet. 2010;11:459–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Tonomura N, Elvers I, Thomas R, Megquier K, Turner-Maier J, Howald C, et al. Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers. PLoS Genet. 2015;11:e1004922.View ArticlePubMedPubMed CentralGoogle Scholar
- Finno CJ, Aleman M, Higgins RJ, Madigan JE, Bannasch DL. Risk of false positive genetic associations in complex traits with underlying population structure: a case study. Vet J. 2014;202:543–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou X, Stephens M. Efficient multivariate linear mixed model algorithms for genome-wide association studies. Nat Methods. 2014;11:407–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, Eskin E. Variance component model to account for sample structure in genome-wide association studies. Nat Genet. 2010;42:348–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Kang HM, Zaitlen NA, Wade CM, Kirby A, Heckerman D, Daly MJ, Eskin E. Efficient control of population structure in model organism association mapping. Genetics. 2008;178:1709–23.View ArticlePubMedPubMed CentralGoogle Scholar
- R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.Google Scholar
- McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26:2069–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.View ArticlePubMedGoogle Scholar
- Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986–94.View ArticlePubMedGoogle Scholar
- Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995–1001.View ArticlePubMedGoogle Scholar
- Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365–86.PubMedGoogle Scholar
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3:RESEARCH0034.Google Scholar
- GraphPad QuickCalcs Web site [http://graphpad.com/quickcalcs/ttest1.cfm].
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.View ArticlePubMedGoogle Scholar
- Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire T, et al. Uncovering regulatory pathways that affect hematopoietic stem cell function using ‘genetical genomics’. Nat Genet. 2005;37:225–32.View ArticlePubMedGoogle Scholar
- Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, et al. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat Genet. 2005;37:233–42.View ArticlePubMedGoogle Scholar
- Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 2005;37:243–53.View ArticlePubMedGoogle Scholar
- Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423–8.View ArticlePubMedGoogle Scholar
- Dobrin R, Zhu J, Molony C, Argman C, Parrish ML, Carlson S, Allan MF, Pomp D, Schadt EE. Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol. 2009;10:R55.View ArticlePubMedPubMed CentralGoogle Scholar
- Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008;5:258–67.View ArticlePubMedPubMed CentralGoogle Scholar
- Gawlik KI, Oliveira BM, Durbeej M. Transgenic expression of Laminin alpha1 chain does not prevent muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Am J Pathol. 2011;178:1728–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Yumoto N, Kim N, Burden SJ. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature. 2012;489:438–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Li M, Dickson DW, Spiro AJ. Abnormal expression of laminin beta 1 chain in skeletal muscle of adult-onset limb-girdle muscular dystrophy. Arch Neurol. 1997;54:1457–61.View ArticlePubMedGoogle Scholar
- Khandjian EW, Bardoni B, Corbin F, Sittler A, Giroux S, Heitz D, et al. Novel isoforms of the fragile X related protein FXR1P are expressed during myogenesis. Hum Mol Genet. 1998;7:2121–8.View ArticlePubMedGoogle Scholar
- Cotten SW, Kornegay JN, Bogan DJ, Wadosky KM, Patterson C, Willis MS. Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am J Transl Res. 2013;6:43–53.PubMedPubMed CentralGoogle Scholar
- Spitali P, van den Bergen JC, Verhaart IE, Wokke B, Janson AA, van den Eijnde R, et al. DMD transcript imbalance determines dystrophin levels. FASEB J. 2013;27:4909–16.View ArticlePubMedGoogle Scholar
- Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D’Amico A, et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J. 2007;21:1210–26.View ArticlePubMedGoogle Scholar
- Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000;151:1321–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet. 2001;27:55–8.PubMedGoogle Scholar
- Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Howard MT, Sampson JB, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat. 2011;32:299–308.View ArticlePubMedPubMed CentralGoogle Scholar
- Disset A, Bourgeois CF, Benmalek N, Claustres M, Stevenin J, Tuffery-Giraud S. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet. 2006;15:999–1013.View ArticlePubMedGoogle Scholar
- Fajkusova L, Lukas Z, Tvrdikova M, Kuhrova V, Hajek J, Fajkus J. Novel dystrophin mutations revealed by analysis of dystrophin mRNA: alternative splicing suppresses the phenotypic effect of a nonsense mutation. Neuromuscul Disord. 2001;11:133–8.View ArticlePubMedGoogle Scholar
- Ginjaar IB, Kneppers AL, v d Meulen JD, Anderson LV, Bremmer-Bout M, van Deutekom JC, Weegenaar J, den Dunnen JT, Bakker E. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet. 2000;8:793–6.View ArticlePubMedGoogle Scholar
- Melis MA, Muntoni F, Cau M, Loi D, Puddu A, Boccone L, Mateddu A, Cianchetti C, Cao A. Novel nonsense mutation (C— > A nt 10512) in exon 72 of dystrophin gene leading to exon skipping in a patient with a mild dystrophinopathy. Hum Mutat. 1998; Suppl 1:S137-138.Google Scholar
- Nishiyama A, Takeshima Y, Zhang Z, Habara Y, Tran TH, Yagi M, Matsuo M. Dystrophin nonsense mutations can generate alternative rescue transcripts in lymphocytes. Ann Hum Genet. 2008;72:717–24.View ArticlePubMedGoogle Scholar
- Shiga N, Takeshima Y, Sakamoto H, Inoue K, Yokota Y, Yokoyama M, Matsuo M. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest. 1997;100:2204–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Gualandi F, Rimessi P, Trabanelli C, Spitali P, Neri M, Patarnello T, et al. Intronic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5’ mutation hot spot of the dystrophin gene. Gene. 2006;370:26–33.View ArticlePubMedGoogle Scholar
- Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, Dubrovsky AL, Viswanathan V, Hoffman EP. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat. 2008;29:728–37.View ArticlePubMedGoogle Scholar
- Gurvich OL, Maiti B, Weiss RB, Aggarwal G, Howard MT, Flanigan KM. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat. 2009;30:633–40.View ArticlePubMedPubMed CentralGoogle Scholar
- McNaughton JC, Hughes G, Jones WA, Stockwell PA, Klamut HJ, Petersen GB. The evolution of an intron: analysis of a long, deletion-prone intron in the human dystrophin gene. Genomics. 1997;40:294–304.View ArticlePubMedGoogle Scholar
- McNaughton JC, Broom JE, Hill DF, Jones WA, Marshall CJ, Renwick NM, Stockwell PA, Petersen GB. A cluster of transposon-like repetitive sequences in intron 7 of the human dystrophin gene. J Mol Biol. 1993;232:314–21.View ArticleGoogle Scholar
- Brinkmeyer-Langford C, Kornegay JN. Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model. Curr Genomics. 2013;14:330–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR et al. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann Neurol. 2012Google Scholar
- Hoffman EP, Gorospe RM. The animal models of Duchenne muscular dystrophy: windows on the pathophysiological consequences of dystrophin deficiency. Curr Top Membr. 1991;38:113–55.View ArticleGoogle Scholar